BioNTech SE

Overview

BioNTech SE is a biotechnology company focused on developing immunotherapies and other medicines for cancer, infectious diseases and serious diseases with unmet medical needs. Its capabilities span research, clinical development, manufacturing and commercialization, and its technology portfolio includes mRNA-based and protein-based approaches. Founded in 2008, BioNTech identifies Comirnaty, its COVID-19 vaccine, as its first marketed pharmaceutical product.[1]+6

The company has an international footprint, with subsidiaries in markets across Europe, Asia, Africa, Australia and North America. For the year ended December 31, 2025, it reported revenue of €2,869.9 million; a third-party company profile reports 7,807 employees as of that date.[8]+3 [1]+11

Products & services

BioNTech’s principal marketed product is COMIRNATY, its COVID-19 vaccine developed with Pfizer. In 2025, an LP.8.1-adapted, monovalent formulation received U.S. FDA approval for adults aged 65 and older and people aged 5–64 at increased risk of severe COVID-19.[12] BioNTech’s commercialization rights for the vaccine cover Germany and Türkiye.[13][14]

Its oncology pipeline includes mRNA cancer immunotherapies and other investigational treatments. BNT113 is an E6/E7-targeting RNA candidate for HPV16-positive head and neck cancer, listed in Phase 2/3 for first-line disease; BNT116 is an mRNA candidate being studied in advanced non-small-cell lung cancer, including a Phase 2 first-line program.[15]+3 BNT211 combines autologous CLDN6-targeted CAR-T cells with CAR-T-amplifying RNA vaccine CARVac.[19][20] The pipeline also lists BNT314/GEN1059, a partnered Phase 1 candidate for solid tumors.[21][22] BioNTech’s 2025 pipeline includes an investigational COVID-19/influenza combination vaccine in Phase 1/2.[23][24]

For FY2025, COVID-19 vaccine revenue was €1,995.3 million, about 70% of total revenue of €2,869.9 million; out-licensing contributed €613.0 million (about 21%) and other revenue €261.6 million (about 9%).[25] Manufacturing capabilities include the Marburg site, which has capacity for up to three billion mRNA drug-substance vaccine doses annually.[26][27] [13]+15

Geographic presence

Germany is BioNTech’s central operating geography, with its headquarters in Mainz and identified sites in Idar-Oberstein, Mainz, Marburg, Martinsried/Neuried and Berlin. The company’s 2025 reporting also lists subsidiaries or registered offices in countries including the United States, China, Singapore, Australia, the United Kingdom, France, Belgium, Austria, Spain, Switzerland, the Netherlands, Israel, Rwanda, Tunisia and Turkey; these listings do not necessarily indicate major operating sites in every country.[28]+2

The manufacturing and research footprint includes Marburg and other German sites, as well as BioNTainer facilities in Kigali, Rwanda, described as having clinical-scale drug-substance and bulk drug-product capacity. Singapore has also been a manufacturing location. At December 31, 2025, BioNTech reported 7,807 FTEs: 6,317 in Europe (about 80.9%), 688 in North America (8.8%), 622 in Asia and Australia (8.0%), and 180 in Africa (2.3%). The reported total includes 674 CureVac FTEs.[31]+2

The 2025 annual report does not provide a geographic breakdown of revenue or sales. In 2026, BioNTech announced plans affecting operations at Idar-Oberstein, Marburg, Singapore and CureVac sites; its August update said it was exploring divestment options for the Idar-Oberstein, Marburg and Singapore manufacturing sites, as well as CureVac and JPT. These were plans or exploratory options, not completed divestments.[32][33] [28]+6

Business segments

BioNTech reports one operating and reportable segment, covering the company as a whole; accordingly, that segment represents 100% of reported operations, and the company does not disclose separate segment-level revenue contributions for its therapeutic areas or technology platforms. Management describes oncology as its primary focus, alongside infectious-disease programs, and works across mRNA-based and protein-based therapeutic approaches.[34]

As a separate revenue-source breakdown—not a segmentation of the business—BioNTech’s 2025 revenue was approximately 70% from COVID-19 vaccines, 21% from out-licensing, and 9% from other revenue.[34] [34][34]

Company history

BioNTech was founded in Mainz in 2008 by Uğur Şahin, Özlem Türeci and Christoph Huber, with an initial focus on developing individualized immunotherapies for cancer. In 2016, it entered a worldwide collaboration with Genentech on individualized mRNA cancer vaccines; in 2018, it announced mRNA vaccine collaborations with Pfizer and the University of Pennsylvania.[35]+3

BioNTech became publicly listed on Nasdaq in 2019. In 2020, it partnered with Pfizer to develop its COVID-19 vaccine program; the vaccine received its first authorization that December and full U.S. FDA approval in 2021. In 2023, BioNTech completed its acquisition of AI company InstaDeep. It completed the acquisition of Biotheus in February 2025 and announced the final results of its CureVac exchange offer in December 2025.[39]+6 [35]+10

Sources

• BioNTech SE — Full financial report (2025 Y)
  28 citations

  [1][2][3][4][5][6][7][8][9][10][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][31]
• stockanalysis.com[11]
• www.biontech.com[12]
• www.biontech.com[30]
• www.biontech.com[32]
• www.biontech.com[33]
• investors.biontech.de[34]
• www.biontech.com[35]
• www.biontech.com[36]
• www.biontech.com[37]
• www.biontech.com[38]
• www.biontech.com[39]
• www.biontech.com[40]
• www.biontech.com[41]
• www.biontech.com[42]
• www.biontech.com[43]
• www.biontech.com[44]
• www.biontech.com[45]